Ultime notizie per Vertiv Hldgs (NYSE:VRT) Azioni

Vertiv Hldgs

Vertiv Holdings Co brings together hardware, software, analytics and ongoing services to ensure its customers vital applications run continuously, perform optimally and grow with their business needs. The company solves the important challenges faced by data centers, communication networks and commercial and industrial facilities with a portfolio of power, cooling and IT infrastructure solutions and services that extends from the cloud to the edge of the network. Its services include critical power, thermal management, racks and enclosures, monitoring and management, and other services. Its three business segments include the Americas, Asia Pacific; and Europe, Middle East & Africa.

Vertiv Holdings

News

Markets

Media

Trading Ideas

Jim Cramer raccomanda un&#39;azione imperdibile: scopri perché questo titolo è considerato un affare da non lasciarsi scappare ora.

Jim Cramer: questo titolo è un affare da non lasciarsi scappare

Vertiv Holdings, LLC Class A Common Stock

Vertiv Holdings Co

Venus Reward Token

Vestin Realty Mortgage II Inc

Veritec Inc

INDIGENOUS BLOOM HEMP CRP by INDIGENOUS BLOOM HEMP CORP

Indigenous Bloom Hemp Corp

VARTECH SYSTEMS INC by Vartech Systems Inc.

Vartech Systems Inc

Virtus Investment Partners, Inc. Common Stock

Virtus Investment Partners Inc

VIATAR CTC SOLUTIONS INC by Viatar CTC Solutions Inc.

Veritiv Corp Com

Vertex Pharmaceuticals Incorporated - Common Stock

Vertex Pharmaceuticals Inc

VERTEX PHARMACEUTICALS ORD

Piper Sandler analyst Matt O'Brien reiterates Sight Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SGHT#NASDAQ">SGHT</a>) with a Neutral and lowers the price target from $6 to $5.5.

Price Target

Reiteration

Analyst Ratings

SGHT

Piper Sandler Reiterates Neutral on Sight Sciences, Lowers Price Target to $5.5

Piper Sandler analyst Alexander Goldfarb maintains Innovative Ind Props (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IIPR#NYSE">IIPR</a>) with a Neutral and lowers the price target from $120 to $118.

IIPR

Piper Sandler Maintains Neutral on Innovative Ind Props, Lowers Price Target to $118

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li><a href="https://www.benzinga.com/analyst-stock-ratings/analyst/587e3d7f5064ed0001730321/charles-neivert">Piper Sandler analyst Charles Neivert</a> downgraded the rating for Celanese Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CE#NYSE">CE</a>) from Neutral to Underweight and lowered the price target from $150 to $98. Celanese shares closed at $89.72 on Thursday. <a href="https://www.benzinga.com/quote/CE/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Macquarie analyst Paul Golding downgraded Planet Fitness, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PLNT#NYSE">PLNT</a>) from Outperform to Neutral but raised the price target from $91 to $99. Planet Fitness shares closed at $94.17 on Thursday. <a href="https://www.benzinga.com/quote/PLNT/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>RBC Capital analyst Mike Dahl downgraded the rating for Installed Building Products, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IBP#NYSE">IBP</a>) from Sector Perform to Underperform and lowered the price target from $203 to $197. Installed Building Prods shares closed at $217.27 on Thursday. <a href="https://www.benzinga.com/quote/IBP/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Barclays analyst Adrienne Yih downgraded Bath &amp; Body Works, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BBWI#NYSE">BBWI</a>) from Equal-Weight to Underweight and lowered the price target from $31 to $28. Bath &amp; Body Works shares closed at $31.75 on Thursday. <a href="https://www.benzinga.com/quote/BBWI/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>William Blair analyst Matt Larew downgraded the rating for Maravai LifeSciences Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRVI#NASDAQ">MRVI</a>) from Outperform to Market Perform. Maravai LifeSciences shares closed at $7.84 on Thursday. <a href="https://www.benzinga.com/quote/MRVI/analyst-ratings">See how other analysts view this stock.</a></li>
</ul>
Considering buying CE stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="539" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/08084942/image-93-1024x539.png" alt="" class="wp-image-637660" style="width:578px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/08084942/image-93-1024x539.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/08084942/image-93-300x158.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/08084942/image-93-768x404.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/08084942/image-93.png 1255w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read More: 
<ul>
<li><a href="https://www.benzinga.com/markets/24/11/41820056/how-to-earn-500-a-month-from-nvidia-stock-after-trump-win">How To Earn $500 A Month From Nvidia Stock After Trump Win</a></li>
</ul>

Downgrades

Pre-Market Outlook

BBWI

MRVI

PLNT

This Celanese Analyst Turns Bearish; Here Are Top 5 Downgrades For Friday

Piper Sandler analyst Matt Farrell reiterates Vivid Seats (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SEAT#NASDAQ">SEAT</a>) with a Neutral and lowers the price target from $5 to $4.

SEAT

Piper Sandler Reiterates Neutral on Vivid Seats, Lowers Price Target to $4

Following Donald Trump&#8217;s win in the 2024 U.S. Presidential election, Jeff Bezos&#8216; net worth has skyrocketed to an unprecedented $228 billion, according to Bloomberg&#8217;s Billionaire Index.
What Happened: Bezos&#8217; wealth, largely connected to his 926.41 million shares in Amazon.com, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>), has surged considerably since Trump's election win.
Tesla and SpaceX CEO Elon Musk currently holds the top position on the Index with a net worth of $290 billion.
On Wednesday, Amazon&#8217;s stock hit a record high of $207.03. This led to Bezos&#8217; net worth climbing by $7 billion, surpassing his previous peak of $221 billion.
See Also:&nbsp;<a href="https://www.benzinga.com/news/24/11/41702294/apple-begins-shifting-iphone-17-production-in-india-cooks-china-optimism-and-more-this-week-in-apple?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Apple Begins Shifting iPhone 17 Production In India, Cook&#8217;s China Optimism, And More: This Week In Appleverse</a>
The market rally on Wednesday also favored the world&#8217;s five wealthiest individuals, including Bezos, who collectively amassed nearly $53 billion.
This surge is largely due to investors&#8217; expectations of decreased&nbsp;regulation and corporate tax cuts&nbsp;under Trump&#8217;s second term.
Subscribe to the&nbsp;<a href="https://bztechtrends.beehiiv.com/subscribe" target="_blank" rel="noreferrer noopener">Benzinga Tech Trends newsletter</a>&nbsp;to get all the latest tech developments delivered to your inbox.
Why It Matters: Prior to the election, <a href="https://www.benzinga.com/markets/equities/24/11/41763411/jeff-bezos-sells-214m-worth-of-amazon-shares-in-latest-stock-move-heres-how-much-he-still-owns">Bezos divested 1.07 million Amazon</a> shares at a price of $200.07 each, earning around $213.8 million.
Amazon posted third-quarter net sales of $158.9 billion, exceeding forecasts and reflecting an 11% year-over-year increase. This strong performance helped boost Amazon's stock price, which <a href="https://www.benzinga.com/news/24/11/41688665/amazon-posts-upbeat-results-joins-cardinal-health-waters-atlassian-charter-communications-mastec-and">climbed notably after the earnings report</a>.
While the Amazon co-founder did not endorse a candidate in this presidential cycle, <a href="https://www.benzinga.com/news/24/11/41796344/tim-cook-mark-zuckerberg-and-jeff-bezos-congratulate-trump-whats-next-for-the-tech-giants">he extended congratulations</a> to Trump on his win, terming&nbsp;it an &#8220;extraordinary political comeback.&#8221;
Bezos and Trump have had ongoing tensions, with the President-elect on multiple occasions publicly criticizing Bezos on social media. In 2018, Trump had accused Amazon of not paying sufficient taxes.
The following year, Amazon sued the Trump administration, claiming the President-elect&#8217;s hostility cost it a $10 billion cloud contract.
Check out more of Benzinga&#8217;s Consumer Tech coverage by&nbsp;<a href="https://www.benzinga.com/topic/consumer-tech" target="_blank" rel="noreferrer noopener">following this link</a>.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/24/11/41737562/trump-vs-harris-meet-the-teens-using-ai-to-call-2024-election-faster-cheaper-than-pollsters?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Trump Vs. Harris: Meet The Teens Using AI To Call 2024 Election Faster, Cheaper Than Pollsters</a></li>
</ul>
Disclaimer: This content was partially produced with the help of&nbsp;<a href="https://www.benzinga.com/author/benzinga-neuro" target="_blank" rel="noreferrer noopener">Benzinga Neuro</a>&nbsp;and was reviewed and published by Benzinga editors.
Image via Shutterstock

Tech

General

AMZN

Jeff Bezos' Net Worth Soars To Record $228B, Closing In On Elon Musk's Top Spot As Amazon Stock Rises After Trump Wins White House

Piper Sandler analyst Rob Owens maintains Fortinet (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FTNT#NASDAQ">FTNT</a>) with a Neutral and raises the price target from $70 to $80.

FTNT

Piper Sandler Maintains Neutral on Fortinet, Raises Price Target to $80

Scotiabank analyst Patrick Colville maintains Dynatrace (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DT#NYSE">DT</a>) with a Sector Outperform and raises the price target from $55 to $62.

Scotiabank Maintains Sector Outperform on Dynatrace, Raises Price Target to $62

WIIM

PEGY

Pineapple Energy shares are trading higher after the company announced distribution to contingent value rights holders.

During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a<a href="https://www.benzinga.com/yield-investments"> high dividend payout</a>.
Benzinga readers can review the latest analyst takes on their favorite stocks by visiting <a href="https://www.benzinga.com/analyst-stock-ratings">Analyst Stock Ratings</a> page. Traders can sort through Benzinga's extensive database of analyst ratings, including <a href="https://www.benzinga.com/analyst-ratings/analyst-color/22/09/28888638/exclusive-study-finds-benzinga-analyst-ratings-data-yields-market-beating-strategie">by analyst accuracy</a>.
Below are the ratings of the most accurate analysts for three high-yielding stocks in the information technology sector.
<h3 class="wp-block-heading">Xerox Holdings Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XRX#NASDAQ">XRX</a>)</h3>
<ul>
<li>Dividend Yield: 11.24%</li>
<li>JP Morgan analyst Samik Chatterjee maintained an Underweight rating and cut the price target from $11 to $8 on Oct. 30. This analyst has an accuracy rate of 70%.</li>
<li>Loop Capital analyst Ananda Baruah maintained a Hold rating and slashed the price target from $14 to $11 on Aug. 14. This analyst has an accuracy rate of 75%.</li>
<li>Recent News: On Oct. 29, Xerox reported worse-than-expected third-quarter financial results and cut annual outlook.</li>
<li>Benzinga Pro's real-time newsfeed alerted to <a href="https://www.benzinga.com/pro/?utm_source=BZprocontent110824&amp;t=be2bearmibe3na1">latest XRX news</a>. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/pro/?utm_source=BZprocontent110824&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="890" height="813" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/08044607/image-88.png" alt="" class="wp-image-637170" style="width:632px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/08044607/image-88.png 890w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/08044607/image-88-300x274.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/08044607/image-88-768x702.png 768w" sizes="(max-width: 890px) 100vw, 890px" /></a></figure>
<h3 class="wp-block-heading">Silicon Motion Technology Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SIMO#NASDAQ">SIMO</a>)</h3>
<ul>
<li>Dividend Yield: 3.57%</li>
<li>Needham analyst Quinn Bolton maintained a Buy rating and cut the price target from $94 to $75 on Nov. 1. This analyst has an accuracy rate of 79%.</li>
<li>Wedbush analyst Matt Bryson reiterated an Outperform rating with a price target of $90 on Oct. 2. This analyst has an accuracy rate of 81%.</li>
<li>Recent News: On Oct. 30, Silicon Motion Technology posted better-than-expected quarterly earnings.</li>
<li>Benzinga Pro's real-time newsfeed alerted to <a href="https://www.benzinga.com/pro/?utm_source=BZprocontent110824&amp;t=be2bearmibe3na1">latest SIMO news</a>. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/pro/?utm_source=BZprocontent110824&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="911" height="821" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/08044643/image-89.png" alt="" class="wp-image-637172" style="width:631px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/08044643/image-89.png 911w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/08044643/image-89-300x270.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/08044643/image-89-768x692.png 768w" sizes="(max-width: 911px) 100vw, 911px" /></a></figure>
<h3 class="wp-block-heading">International Business Machines Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IBM#NYSE">IBM</a>)</h3>
<ul>
<li>Dividend Yield: 3.13%</li>
<li>BMO Capital analyst Keith Bachman maintained a Market Perform rating and raised the price target from $235 to $260 on Oct. 24. This analyst has an accuracy rate of 81%.</li>
<li>Jefferies analyst Brent Thill maintained a Hold rating and increased the price target from $200 to $245 on Oct. 21. This analyst has an accuracy rate of 77%.</li>
<li>Recent News: On Oct. 23, IBM reported third-quarter revenue of $14.968 billion, missing the consensus estimate of $15.07 billion, according to Benzinga Pro. The company reported quarterly loss from continuing operations of 34 cents per share.</li>
<li>Benzinga Pro&#8217;s charting tool helped identify the <a href="https://www.benzinga.com/pro/?utm_source=BZprocontent110824&amp;t=be2bearmibe3na1">trend in IBM stock</a>. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/pro/?utm_source=BZprocontent110824&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="910" height="821" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/08044754/image-90.png" alt="" class="wp-image-637173" style="width:632px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/08044754/image-90.png 910w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/08044754/image-90-300x271.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/08044754/image-90-768x693.png 768w" sizes="(max-width: 910px) 100vw, 910px" /></a></figure>
<figure class="wp-block-embed is-type-video is-provider-youtube wp-block-embed-youtube wp-embed-aspect-16-9 wp-has-aspect-ratio"> 
<div class="wp-block-embed__wrapper">
<iframe loading="lazy" title="How to Find Dividend Stocks: Scan, Analyze, and Capture with Benzinga Pro" width="500" height="281" src="https://www.youtube.com/embed/pVF0O2lsEH4?start=1&#038;feature=oembed" frameborder="0" allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share" referrerpolicy="strict-origin-when-cross-origin" allowfullscreen></iframe>
</div>
</figure>
Read More: 
<ul>
<li><a href="https://www.benzinga.com/markets/24/11/41820056/how-to-earn-500-a-month-from-nvidia-stock-after-trump-win">How To Earn $500 A Month From Nvidia Stock After Trump Win</a></li>
</ul>

Dividends

SIMO

Wall Street's Most Accurate Analysts Spotlight On 3 Tech Stocks With Over 3% Dividend Yields

Piper Sandler analyst Matt O'Brien maintains TELA Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TELA#NASDAQ">TELA</a>) with a Overweight and lowers the price target from $8 to $5.

TELA

Piper Sandler Maintains Overweight on TELA Bio, Lowers Price Target to $5

U.S. stock futures were slightly lower this morning, with the Nasdaq futures falling around 0.2% on Friday.
Shares of Sweetgreen, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SG#NYSE">SG</a>) fell sharply in today's pre-market trading after the company reported worse-than-expected <a href="https://www.benzinga.com/quote/SG/earnings">quarterly financial results</a>.
Sweetgreen reported a quarterly loss of 18 cents per share, compared to market expectations for a loss of 16 cents per share. The company reported quarterly sales of $173.400 million which missed the analyst consensus estimate of $175.533 million.
Sweetgreen shares dipped 15% to $35.87 in the pre-market trading session.
Here are some other stocks moving lower in pre-market trading.
<ul>
<li>Evolent Health, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EVH#NYSE">EVH</a>) shares fell 33.6% to $16.31 in pre-market trading after the company reported worse-than-expected third-quarter financial results.</li>
<li>agilon health, inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AGL#NYSE">AGL</a>) shares fell 29% to $1.98 in pre-market trading after the company reported worse-than-expected quarterly revenue results.</li>
<li>Maravai LifeSciences Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRVI#NASDAQ">MRVI</a>) declined 26.6% to $5.75 in pre-market trading after the company reported worse-than-expected third-quarter financial results and cut its FY24 sales guidance.</li>
<li>Redfin Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RDFN#NASDAQ">RDFN</a>) fell 14.1% to $9.85 in pre-market trading after the company reported worse-than-expected third-quarter financial results.</li>
<li>Pinterest, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PINS#NYSE">PINS</a>) shares dipped 12.7% to $29.62 in pre-market trading after the company reported worse-than-expected third-quarter EPS results.</li>
<li>Pacific Biosciences of California, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PACB#NASDAQ">PACB</a>) dipped 12.6% to $2.14 in pre-market trading after the company reported worse-than-expected third-quarter revenue results.</li>
<li>The Trade Desk, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TTD#NASDAQ">TTD</a>) declined 9.7% to $119.62 in pre-market trading following third-quarter results.</li>
<li>DraftKings Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DKNG#NASDAQ">DKNG</a>) fell 5.2% to $36.97 in pre-market trading after the company reported worse-than-expected third-quarter revenue results and lowered its FY24 revenue guidance..</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/markets/24/11/41820056/how-to-earn-500-a-month-from-nvidia-stock-after-trump-win">How To Earn $500 A Month From Nvidia Stock After Trump Win</a></li>
</ul>

Movers

DKNG

PACB

PINS

RDFN

Sweetgreen Posts Downbeat Results, Joins Evolent Health, Redfin, Pinterest And Other Big Stocks Moving Lower In Friday's Pre-Market Session

AstraZeneca Plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AZN#NASDAQ">AZN</a>) and Amgen Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMGN#NASDAQ">AMGN</a>) released topline data from the Phase 3 WAYPOINT trial of Tezspire (tezepelumab) in patients with chronic rhinosinusitis with nasal polyps (CRSwNP [nasal polyps])
The data <a target="_blank" href="https://www.astrazeneca.com/media-centre/press-releases/2024/tezspire-nasal-polyps-trial-met-primary-endpoints.html" rel="noreferrer noopener">showed</a> that Tezspire&nbsp;demonstrated a statistically significant and clinically meaningful reduction in the size of nasal polyps and reduced nasal congestion compared to placebo.
Also Read: <a target="_blank" href="https://www.benzinga.com/analyst-ratings/analyst-color/24/04/38299995/amgenastrazenecas-asthma-drug-tezspire-vs-sanofiregenerons-blockbuster-dupixent-ana" rel="noreferrer noopener">Amgen/AstraZeneca&#8217;s Asthma Drug Tezspire Vs. Sanofi/Regeneron&#8217;s Blockbuster Dupixent &#8211; Analyst Gives His Pick</a>
WAYPOINT is a randomized, double-blind trial that evaluated the efficacy and safety of&nbsp;Tezspire&nbsp;administered subcutaneously compared to placebo in adults with severe CRSwNP.
Participants in the trial were symptomatic despite treatment with standard of care (intranasal corticosteroids [INCS]).
Chronic rhinosinusitis with nasal polyps is&nbsp;a condition that can cause symptoms from sinus pain and nose stuffiness to loss of smell. Nasal polyps are growths in the nose or sinuses.
The safety profile and tolerability of&nbsp;Tezspire in this trial were consistent with the known profile of the medicine.
Full results will be shared with regulatory authorities and the scientific community at an upcoming medical meeting.
Tezspire&nbsp;is currently approved for severe asthma in the US, EU, Japan, and nearly 60 countries.
It is approved as a single-use pre-filled syringe and auto-injector for self-administration in the US and EU.
In May, the companies announced the results of the Phase 2a COURSE trial of Tezspire for severe chronic obstructive pulmonary disease (COPD) with a broad range of baseline blood eosinophil counts (BEC) irrespective of emphysema, chronic&nbsp;bronchitis, <a target="_blank" href="https://www.benzinga.com/general/biotech/24/05/38924821/amgenastrazeneca-say-asthma-drug-shows-activity-in-another-lung-disease-across-broad-patient-popu" rel="noreferrer noopener">or smoking status</a>.&nbsp;
The primary results showed that treatment with Tezspire led to a 17% numerical reduction in the annual rate of moderate or severe COPD exacerbations compared to placebo at week 52, which was not statistically significant.
Price Action: AMGN stock closed at $321.91 on Thursday, and AZN stock is up 0.11% at $64.76 during the premarket session at the last check on Friday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/11/41820820/solaredge-q3-results-miss-expectations-analysts-warn-of-cash-flow-challenges-and-ne" target="_blank" rel="noreferrer noopener">SolarEdge Q3 Results Miss Expectations; Analysts Warn Of Cash Flow Challenges And Need For Cost Cuts</a></li>
</ul>

Biotech

Large Cap

Health Care

AMGN

AstraZeneca/Amgen's Asthma Drug Aces Late-Stage Study In Patients With Chronic Rhinosinusitis

Piper Sandler analyst Matt Farrell reiterates Trade Desk (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TTD#NASDAQ">TTD</a>) with a Overweight and raises the price target from $110 to $140.

Piper Sandler Reiterates Overweight on Trade Desk, Raises Price Target to $140

Pineapple Energy Inc. (NASDAQ:<a href="https://www.benzinga.com/stock/PEGY#NASDAQ">PEGY</a>) ("Pineapple" or the "Company"), a leading provider of sustainable solar energy and backup power to households, businesses, municipalities, and for servicing existing systems, today announced that it will distribute to the holders of its non-transferable Contingent Value Rights ("CVRs") a payment of $850,269, or $0.35 per CVR.

Pineapple Energy Announces That It Will Distribute To The Holders Of Its Non-Transferable Contingent Value Rights A Payment Of $850,269, Or $0.35 Per CVR

INDI

Indie Semiconductor shares are trading higher after the company reported better-than-expected Q3 financial results.

Scotiabank analyst Patrick Colville maintains Datadog (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DDOG#NASDAQ">DDOG</a>) with a Sector Outperform and lowers the price target from $135 to $133.

DDOG

Scotiabank Maintains Sector Outperform on Datadog, Lowers Price Target to $133

Servotronics (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/SVT#AMEX">SVT</a>) reported quarterly losses of $(0.20) per share. This is a 122.22 percent decrease over losses of $(0.09) per share from the same period last year. The company reported $12.43 million in sales this quarter. This is a 7.32 percent increase over sales of $11.58 million the same period last year.

Earnings

Servotronics Q3 EPS $(0.20) Down From $(0.09) YoY, Sales $12.43M Up From $11.58M YoY

RVNC

Revance Therapeutics shares are trading lower after the company reported better-than-expected Q3 EPS results.

Piper Sandler analyst Alexander Potter maintains ACV Auctions (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACVA#NASDAQ">ACVA</a>) with a Neutral and raises the price target from $16 to $18.

ACVA

Piper Sandler Maintains Neutral on ACV Auctions, Raises Price Target to $18

The holiday season brings joy, family gatherings and sometimes, stress.
For those considering cannabis as a natural way to ease holiday nerves and connect with loved ones, one of Vermont's largests cannabis brands, Upstate Elevator Supply Co. has introduced the Happy Days and Dreamy Nights THC gummy bundle. With a mix of daytime and nighttime formulas, this set of microdosed gummies offers an option for a balanced, relaxing holiday experience.
See Also: <a href="https://www.benzinga.com/markets/cannabis/22/01/24922189/report-americans-are-celebrating-traditional-holidays-with-cannabis-spend-millions-doing-so">Report: Americans Are Celebrating Traditional Holidays With Cannabis, Spend Millions Doing So</a>
In this guide, we'll walk you through practical tips from Kelsy Raap, a certified community herbalist and Upstate's director of outreach and education, on how to incorporate cannabis into your holiday gatherings.
<h3 class="wp-block-heading">Microdosing 101: How To Start Small</h3>
For those trying cannabis edibles for the first time, particularly in a family setting, Raap recommends beginning with a microdose. "Start low," she advises. "One milligram is a good place to start for somebody that's never used cannabis or who doesn't use it regularly." 
Upstate's gummy pucks are pre-scored into precise 2mg wedges, allowing users to choose a small amount and adjust as needed. For newcomers, Raap suggests staying below 5mg, especially during social gatherings where moderation can make for a smoother experience.
To enhance the benefits while keeping the experience mellow, consider formulas that balance THC with other cannabinoids like CBD, CBG or CBN. "These compounds help balance the THC so that it doesn't feel quite as altering," Raap explains. For first-timers, this balance can provide all the therapeutic effects of THC without an overwhelming high.
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1022" height="1024" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/07194408/Happy-Days-Dreamy-Nights-Gummies-1022x1024.jpg" alt="" class="wp-image-636585" style="width:360px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/07194408/Happy-Days-Dreamy-Nights-Gummies-1022x1024.jpg 1022w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/07194408/Happy-Days-Dreamy-Nights-Gummies-300x300.jpg 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/07194408/Happy-Days-Dreamy-Nights-Gummies-150x150.jpg 150w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/07194408/Happy-Days-Dreamy-Nights-Gummies-768x769.jpg 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/07194408/Happy-Days-Dreamy-Nights-Gummies.jpg 1078w" sizes="(max-width: 1022px) 100vw, 1022px" /><figcaption class="wp-element-caption">Image courtesy: Upstate Elevator.</figcaption></figure>
<h3 class="wp-block-heading">Easing Holiday Stress: How THC And CBD Work Together</h3>
Holiday stress is common, and for many, cannabis offers a natural way to manage it. Raap explains how the combined effects of CBD and THC can support relaxation, each working differently to calm the body and mind. 
"CBD, the non-intoxicating component, is great for helping us calm down, for helping sort of ease the mind in a very subtle, gentle way," she says. THC, on the other hand, can provide a more immediate sense of relaxation at low doses, making it a good choice for those who want to unwind without feeling overly sedated. Even a small amount, about one milligram, can soothe the nervous system and bring a sense of calm.
Microdosing THC, especially in social situations, can also help people take a step back from potentially tense conversations, adding a layer of objectivity. Raap notes that, at low doses, THC "helps us kind of zoom out, pull back, see things from a little bit more of a holistic perspective, and feel a little bit less personally involved in a conflict." For holiday gatherings where emotions might be heightened, especially after the U.S. elections, this approach can foster a more relaxed and open atmosphere.
<h3 class="wp-block-heading">Bringing Cannabis To The Family Table: How To Build Comfort And Trust</h3>
Cannabis at family occasions is gradually becoming more normalized, and Raap has seen this shift firsthand. 
 "One of my favorite things is when a customer walks into our store, who's, you know, 35, 40 years old, and they're bringing their parents in with them," she shares. This shift is often met with curiosity and surprise as parents rediscover cannabis, especially in a low-dose, controlled form.
Raap points out that today's cannabis products come with clear labeling and rigorous testing, which can ease the concerns of older generations. "There's a lot more trust in the companies now, right? Because everything is tested," she notes. 
For older adults, the transparency of listed ingredients and lab-tested dosages can offer peace of mind. These products are created to help bridge generations, allowing young adults to share the benefits of cannabis with their parents or grandparents in a safe, enjoyable way.
<h3 class="wp-block-heading">How to Talk Your Family Into Microdosing THC This Holiday Season</h3>
Introducing cannabis at family gatherings can be met with hesitation, but Raap offers a straightforward approach. "If a family is happy with the dynamics—if they&#8217;re mostly peaceful and calm, if they don&#8217;t have any challenges with fighting over politics or religion—then you don't need it." 
However, for families who find themselves in tense discussions or who want to keep things light, microdosing can be beneficial. "If a family is looking for a tool to help them have less reactivity during the holidays and be less reactive&#8230;this is a great tool."
For those worried about acting unpredictably, Raap reassures, "This isn't like alcohol, right? You're not going to make a fool of yourself if you use cannabis; you're not going to make poor decisions."
See Also: <a href="https://www.benzinga.com/markets/cannabis/19/04/13533938/a-really-nice-entry-point-cannabis-microdosing-and-who-its-for">&#8216;A Really Nice Entry Point&#8217;: Cannabis Microdosing And Who It&#8217;s For</a>
When legal concerns come up, Raap suggests focusing on the benefits. "Consider whether you're looking for the therapeutic application. There are different ways to use cannabis. You can use it therapeutically, you can use it recreationally."
<h3 class="wp-block-heading">Quick Tips For First-Time Edible Users</h3>
Here are Raap's top tips for a positive experience:
<ol>
<li>Start Low and Go Slow: For beginners, 1-2mg is a good starting point,and 5mg should be the upper limit for those less experienced with THC.</li>
<li>Balance with CBD: Look for formulas that blend THC with other cannabinoids like CBD to create a balanced effect.</li>
<li>Be Prepared for Too Much: If you or someone feels "too high," Raap suggests taking a large dose of CBD, which can help mitigate THC's psychoactive effects and bring you back to a more comfortable level. "Using a large dose of CBD will mitigate the psychoactivity," she says.</li>
</ol>
<h3 class="wp-block-heading">Beyond The Holidays: A Healthier Alternative To Alcohol</h3>
If you're considering cutting back on alcohol this New Year, cannabis may be a fun, non-alcoholic alternative. "I could still have three or four of these while my friends are drinking their six-pack of beer," Raap suggests, while pointing at one of Upstate&#8217;s THC beverages. 
THC allows for a festive mood without the dehydrating, hangover-inducing effects of alcohol, making it an appealing option for those looking to moderate their drinking habits.
THC can also help support mental wellness during the winter months. For those prone to seasonal depression or daily anxiety, Raap recommends a more consistent approach, integrating cannabis into a daily wellness routine. 
"For folks that experience anxiety and stress every single day…planning to implement a daily practice with CBD and or low-dose THC is a good idea," she explains. Microdosing daily or as needed can help build resilience against winter blues.
<h3 class="wp-block-heading">Will Cannabis Become The New Alcohol At Family Gatherings?</h3>
Looking toward the future, Raap says she hopes cannabis will eventually be as accepted as alcohol at family events. "Honestly, I think that alcohol eventually is going to go the way of cigarettes," she says.
However, she notes that federal legalization would likely be necessary for widespread acceptance. "A lot of people still trust the government, and if the government says it's bad for you, they believe it," Raap added.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/cannabis/24/07/39585412/hand-in-hand-progressive-reform-galvanizes-interest-in-microdosing-new-study-shows">Reform Is Pushing Curiosity In Microdosing, Study Shows</a></li>
</ul>
Cover image made with AI.

Cannabis

Exclusives

Interview

How To Microdose Cannabis For Stress-Free Holiday Season: Tips For Newcomers

In a report released yesterday, Stephen Tusa from J.P. Morgan maintained a Buy rating on Vertiv Holdings (VRT – Research Report), with a price targ...

Optimistic Buy Rating for Vertiv Holdings: Strong Q3 Performance and Promising Growth Prospects

BofA raised the firm's price target on Vertiv Holdings (VRT) to $140 from $130 and keeps a Buy rating on the shares. Vertiv is "translating strong ...

Vertiv Holdings price target raised to $140 from $130 at BofA

Mizuho raised the firm's price target on Vertiv Holdings (VRT) to $125 from $110 and keeps an Outperform rating on the shares post the Q3 report. T...

Vertiv Holdings price target raised to $125 from $110 at Mizuho

TD Cowen analyst Lance Vitanza raised the firm's price target on Vertiv Holdings (VRT) to $115 from $93 and keeps a Buy rating on the shares. The f...

Vertiv Holdings price target raised to $115 from $93 at TD Cowen

Oppenheimer raised the firm's price target on Vertiv Holdings (VRT) to $121 from $115 and keeps an Outperform rating on the shares. The firm notes ...

Vertiv Holdings price target raised to $121 from $115 at Oppenheimer

In a report released today, Amit Daryanani from Evercore ISI maintained a Buy rating on Vertiv Holdings (VRT – Research Report), with a price targe...

Evercore ISI Sticks to Their Buy Rating for Vertiv Holdings (VRT)

Evercore ISI raised the firm's price target on Vertiv Holdings (VRT) to $135 from $125 and keeps an Outperform rating on the shares after the compa...

Vertiv Holdings price target raised to $135 from $125 at Evercore ISI

Mizuho Securities analyst Brett Linzey has assigned their bullish stance on VRT stock, giving a Buy rating today. Brett Linzey's rating is based on...

Comments

Vertiv Hldgs

Notizie

Ultime notizie per Vertiv Hldgs (NYSE:VRT) Azioni

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO